Land: Australien
Sprog: engelsk
Kilde: Department of Health (Therapeutic Goods Administration)
Isosorbide mononitrate
Apotex Pty Ltd
Medicine Registered
CHEMMART ISOSORBIDE MONONITRATE TABLETS _contains the active ingredient, Isosorbide mononitrate_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET READ THIS LEAFLET CAREFULLY BEFORE TAKING YOUR MEDICINE. ASK YOUR DOCTOR OR PHARMACIST IF YOU DO NOT UNDERSTAND ANYTHING OR ARE WORRIED ABOUT TAKING YOUR MEDICINE. This leaflet answers some of the common questions people ask about Isosorbide Mononitrate Sustained- Release tablets. It does not contain all the information that is known about isosorbide mononitrate. It does not take place of talking to your doctor or pharmacist. The information in this leaflet was last updated on the date listed on the last page. Some more recent information on your medicine may be available. Speak to your pharmacist or doctor to obtain the most up-to-date information. All medicines have risks and benefits. Your doctor has weighed the risks of you taking isosorbide monontrate against the benefits they expect it will have for you. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT IS ISOSORBIDE MONONITRATE USED FOR The name of your medicine is Chemmart Isosorbide Mononitrate Sustained-Release tablets. It is used to prevent angina. Angina is a pain or uncomfortable feeling in the chest, often spreading to the arms or the neck and sometimes to the shoulders and back. This is caused by to little blood and oxygen getting to the heart. The pain of angina is usually brought on by exercise or stress. _HOW IT WORKS_ Isosorbide mononitrate belongs to a group of medicines called nitrates. It works by relaxing the blood vessels, letting more blood and oxygen reach the heart. It is not recommended that isosorbide mononitrate be taken for the treatment of acute attacks. Your doctor will have explained why you are being treated with isosorbide mononitrate and told you what dose to take. FOLLOW ALL DIRECTIONS GIVEN TO YOU BY YOUR DOCTOR CAREFULLY. They may differ from the information contained in this leaflet. However, your doctor may prescribe this medicine for Læs hele dokumentet
Product Information – Australia CHEMMART ISOSORBIDE MONONITRATE TABLETS NAME OF THE MEDICINE Isosorbide Mononitrate Sustained Release Tablets. Chemical Name: 1,4:3,6-dianhydro-D-glucitol 5-nitrate. Chemical Structure: Molecular Formula: C 6 H 9 NO 6 Molecular Weight: 191.14 CAS Registry Number: 16051-77-7 DESCRIPTION Isosorbide mononitrate is a white to pale yellow, crystalline, odourless powder that is freely soluble in water. PHARMACOLOGY Isosorbide mononitrate is an active metabolite of isosorbide dinitrate and exerts qualitatively similar effects. Isosorbide mononitrate reduces the workload of the heart by producing venous and arterial dilatation. By reducing the end diastolic pressure and volume, isosorbide mononitrate lowers intramural pressure, hence leading to an improvement in the sub-endocardial blood flow. The net effect when administering isosorbide mononitrate is therefore a reduced workload for the heart and an improvement in the oxygen supply/demand balance of myocardium. Nitrates are highly effective in the prophylaxis of symptomatic and asymptomatic myocardial ischaemia. Nitrates dilate coronary arteries not only in pre- and post-stenotic vessels, but also in eccentric lesions. The natural initiator of vascular relaxation is thought to be endothelium derived relaxing factor (EDRF), which has both the clinical and biological characteristics of nitric oxide. Organic nitrates are metabolised to nitric oxide in the muscle cell via a sulfhydryl dependent mechanism. They are therefore thought to be the physiological substitute for EDRF. PHARMACOKINETICS Isosorbide mononitrate has an elimination half-life of around 5 hours. Isosorbide Mononitrate 60 mg Sustained Release Tablets provide a sustained release presentation of isosorbide mononitrate, with approximately 85% bioavailability. The release mechanism in Chemmart Isosorbide Mononitrate comprises acti Læs hele dokumentet